These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 3692826)
21. Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa. Pal PK; Sathyaprabha TN; Tuhina P; Thennarasu K Mov Disord; 2007 Feb; 22(3):420-4. PubMed ID: 17230476 [TBL] [Abstract][Full Text] [Related]
22. Bruxism as presenting feature of Parkinson's disease. Srivastava T; Ahuja M; Srivastava M; Trivedi A J Assoc Physicians India; 2002 Mar; 50():457. PubMed ID: 11922248 [No Abstract] [Full Text] [Related]
23. [Treatment of Parkinson's disease associated with psychosis]. Ombrato M; Capone D Clin Ter; 1975 Aug; 74(3):293-7. PubMed ID: 1227749 [No Abstract] [Full Text] [Related]
24. Further comments on swallowing in Parkinson's disease. Nilsson H Dysphagia; 1997; 12(2):98-9. PubMed ID: 9071811 [No Abstract] [Full Text] [Related]
25. Color vision impairment in Parkinson's disease. Piro A; Tagarelli A; Nicoletti G; Fletcher R; Quattrone A J Parkinsons Dis; 2014; 4(3):317-9. PubMed ID: 24796233 [No Abstract] [Full Text] [Related]
26. [Secondary effects of prolonged levodopa therapy in Parkinson's disease]. Peiró Grasa A; Grau-Veciana JM Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630 [No Abstract] [Full Text] [Related]
27. Parkinson's disease. Clarke C; Moore AP Clin Evid; 2005 Jun; (13):1658-77. PubMed ID: 16135305 [No Abstract] [Full Text] [Related]
28. [Motor complications in patients with Parkinson disease treated with levodopa]. Luquin MR; Obeso JA; Martínez-Lage JM Neurologia; 1989; 4(1):4-11. PubMed ID: 2631806 [TBL] [Abstract][Full Text] [Related]
29. Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude. Sharp ME; Viswanathan J; McKeown MJ; Appel-Cresswell S; Stoessl AJ; Barton JJ Neuropsychologia; 2013 Nov; 51(13):2679-89. PubMed ID: 23954375 [TBL] [Abstract][Full Text] [Related]
30. Parkinson's disease and pain--nondopaminergic mechanisms are likely to be important too. Lim SY; Farrell MJ; Evans AH Mov Disord; 2011 Jun; 26(7):1353-4. PubMed ID: 21449013 [No Abstract] [Full Text] [Related]
31. [Parkinson's disease following hypothyroidism: clinical and therapeutic implications]. Kacem I; Gargouri A; Ben Djebara M; Khamassi N; Cherif W; Gouider R Tunis Med; 2013 Feb; 91(2):168-70. PubMed ID: 23526270 [No Abstract] [Full Text] [Related]
32. Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature. Zanetti R; Loria D; Rosso S Melanoma Res; 2006 Jun; 16(3):201-6. PubMed ID: 16718266 [TBL] [Abstract][Full Text] [Related]
33. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study]. Liashchenko EA; Skripkina NA; Levin OS Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933 [TBL] [Abstract][Full Text] [Related]
34. [Disturbance of micturition in Parkinson's disease]. Sakakibara R; Uchiyama T; Yoshiyama M; Hattori T No To Shinkei; 2001 Nov; 53(11):1009-14. PubMed ID: 11761908 [No Abstract] [Full Text] [Related]
35. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia. Vidal EI; Fukushima FB; Valle AP; Villas Boas PJ J Am Geriatr Soc; 2013 Jan; 61(1):170-2. PubMed ID: 23311565 [No Abstract] [Full Text] [Related]
36. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease. Walker RW; Howells AR; Gray WK Parkinsonism Relat Disord; 2011 Jan; 17(1):27-9. PubMed ID: 21051272 [TBL] [Abstract][Full Text] [Related]
37. [Non-motor fluctuations in Parkinson's disease]. Levin OS; Smolentseva IG; Ivanov AK Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3):90-6. PubMed ID: 20607929 [No Abstract] [Full Text] [Related]